Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib Study of TPN672 in Schizophrenia
NCT05192304Phase 1Unknown
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd.
- Start
- Feb 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TPN-672 in schizophrenia (6 arms), sponsored by Jiangsu Kanion Pharmaceutical Co., Ltd. Primary endpoints: Adverse events at Day 14 and Blood pressure at Day 14. Status: unknown.
02
Drugs
TPN-672
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05192304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05192304.